General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Servier Canada Inc.
Indication:
For the treatment of Grade 2 WHO 2016, 2021 grading system astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.
Last updated February 19, 2026
Status:
Concluded with an LOI
Manufacturer:
EMD Serono Canada, a division of EMD Inc.
Indication:
Multiple Sclerosis, Relapsing-Remitting
Last updated February 12, 2026
Status:
Active negotiation
Manufacturer:
Ferring Canada Inc.
Indication:
Clostridioides difficile infection, prevention
Last updated February 11, 2026
Status:
Active negotiation
Manufacturer:
Idorsia Pharmaceuticals Canada Ltd.
Indication:
Insomnia
Last updated February 11, 2026
Carvykti (ciltacabtagene autoleucel)
Status:
Active negotiation
Manufacturer:
Janssen Inc.
Indication:
For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
Last updated February 6, 2026
Carvykti (ciltacabtagene autoleucel)
Status:
Active negotiation
Manufacturer:
Janssen Inc.
Indication:
Multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment
Last updated February 6, 2026
Status:
Concluded without agreement
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Idiopathic pulmonary fibrosis and PF-ILD
Last updated February 5, 2026
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
Last updated February 3, 2026
Status:
Concluded without agreement
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Generalized pustular psoriasis (GPP)
Last updated February 3, 2026
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy
Last updated January 29, 2026